



Bi-Test™ CD7 FITC-CD13&33 PE

Product: Anti-human T cells, anti human Myelomonocytic Monoclonal and anti human Myeloid Monoclonal Antibodies.

Description: Identification of human T lymphocytes in multiple stages of T cell development, including a major subset of mature peripheral T cells. CD7 antigen is often increased on T leukemic cells. The CD7 molecule is a 40,000 M.W. surface antigen that is expressed on T-Lymphoid and myeloid precursors in fetal liver and bone marrow. CD13 is a membrane enzyme Aminopeptidase N. Identification of human monocytes and granulocytes expressing the 150 kD M.W. surface antigen. Myeloid cells in regenerating bone marrow will have an increased expression of CD13 in comparison with normal bone marrow myeloid cells. Identification of human Monocytes(bright) and Granulocytes (dim) expressing the 67K M.W. surface antigen. CD33 is also found on CFU-mix, CFU-GM, CFU-Meg, a portion of BFU-E, myeloblasts, promyelocytes, myelocytes, metamyelocytes but not early precursors.

Isotype: Mouse IgG2a kappa (FITC) IgG1 kappa (PE) and IgG1 kappa (PE).

Clone: G34. (CD7 FITC), E735.0 (CD13 PE) and FOS (CD33 PE).

Applications: Monitoring of T cells in peripheral blood; Study of T cell leukemia's and lymphoma's; Study of cell mediated cytotoxicity; Study of bone marrow transplantation; Characterization of subtypes of leukemias and lymphomas; Studies of AIDS virus infection; Myeloid cell function studies; Analysis of hematopoietic maturation.

Use: PBMC: Add 10 μ l of MAB/10⁶ PBMC in 100 μ l PBS. Mix gently and incubate for 15 minutes at 2⁰ to 8⁰C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze.

WHOLE BLOOD: Add 10 μ l of MAB/100 μ l of whole blood. Mix gently and incubate for 15 minutes at room temperature 20⁰C. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer's instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.

Storage: Antibodies are supplied in PBS, 0.08% sodium azide, and 0.2% protein carrier for Pure, FITC, Biotin and PE. Antibodies should be stored at 4-8⁰C. Monoclonal antibodies should not be frozen. Reagents are stable for the period shown on the vial label when stored properly.

Ordering Information:	Form	Vial Size	Catalog #
	Bi-Test™	50 Test	71333s
	Bi-Test™	100 Test	71333

For research use only. Not for use in human diagnostics or therapeutics.

REFERENCES:

1. Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine Thy-1 gene. Schanberg, L.E., Fleener, D.E., Kurtzberg, J., Haynes, B.F., Kaufman, R.E.; Proc. Natl. Acad. Sci. USA , 1991 Jan 1;88(2):603-7.
2. Identification of novel B-lineage cells in human fetal bone marrow that coexpress CD7. Grumayer, E.R., Griesinger, F., Hummell, D.S., Brunning, R.D., Kersey, J.H.; Blood, 1991 Jan ; 77(1):64-8.
3. Genuine CD7 expression in acute leukemic and lymphoblastic lymphoma. Osada, H., Emi, N., Ueda, R., Seto, M., Koike, K., Suchi, T., Kojima, S., Obata, Y., Takahashi, T.; Leuk. Res. 1990;14(10):869-77.
4. Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine. Akbar, A.N., Amlot, P.L., Ivory, K., Timms, A., Janossy, G.; Transplantation, 1990 No;50(5):823-9.
5. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand, R., Vannier, J.P., Bene, M.C., Faure, G., Favre, M., Bernard, A.; Leukemia, 1990 No;4(11):739-44.
6. Induction of CD13 expression on fresh myeloid leukemia: correlation of CD13 expression with aminopeptidase-N activity. Razak K; Newland AC Leuk Res 1992 Jun-Jul;16(6-7):625-30
7. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4
8. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A Cancer 1992 Jan 15;69(2):396-404
9. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T Acta Haematol 1992;87(1-2):88-93
10. Immunologic Classification of Leukemia and Lymphoma. Foon, K.A. , Todd, III, R.F. (1986)(1986) Blood ,68, 1
11. Surface marker expression in acute myeloid leukaemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4
12. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM; et al Blood 1992 May 1;79(9):2229-36
13. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. Dinndorf PA; Buckley JD; Nesbit ME; Lampkin BC; Piomelli S; Feig SA; Kersey JH; Hammond GD; Bernstein ID Med Pediatr Oncol 1992;20(3):192-200
14. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S; et al Blood 1992 Apr 1;79(7):1811-6
15. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Buccheri V; Shetty V; Yoshida N; Morilla R; Matutes E; Catovsky D Br J Haematol 1992 Jan;80(1):62-8

For research use only. Not for use in human diagnostics or therapeutics.

Exalpha Biologicals, Inc., 2 Shaker Rd, #B101, Shirley, MA 01464
Tel: 800.395.1137 or 978.425.1370, Fax: 866.924.5100 or 978.425.1376, Web: www.exalpha.com